Daria Kutsakina

Mrs. Daria Kutsakina

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
PDF file
EZElena Zheleznykh
Elena Zheleznykh
APAnastasia Panova
Anastasia Panova
AEAleksei Emelianov
Aleksei Emelianov
DKDaria Kutsakina
Daria Kutsakina
ANAndrei Nartov
Andrei Nartov
MKMaria Kozhevnikova
Maria Kozhevnikova
Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months. [...] Abstract Background: Patients with chronic heart failure (HF) require outpatient monitoring after hospital discharge. The ability to use a smartphone with a personal messaging application may help. Objectives: Tis study aimed to investigate the feasibility of remote monitoring and evaluate its impact on treatment adherence and prognosis in patients with HF. Methods: A total of 100 patients were enrolled in the study: 57 patients in the mHealth group and 43 in the control group. The observation period lasted six months.

28 December 2025 in Kardiologiia
Verified
Journal Article
Closed access
DKDaria Kutsakina
Daria Kutsakina
NKN. V. Khabarova
N. V. Khabarova
EPE. V. Privalova
E. V. Privalova
YBYuri Belenkov
Yuri Belenkov
III. S. Ilgisonis
I. S. Ilgisonis
Aim To study the concentrations of routine markers of systemic inflammation (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen) and assess their correlation with the vascular morpho-functional parameters in patients with hemoblastosis before the start of polychemotherapy. Material and methods The study included 32 patients with a newly diagnosed oncohematological disease, with 18 (56.25%) men aged 56.87±17.06 years (95% confidence interval (CI): 50.50-63.24). For all patients, ESR, CRP, and fibrinogen concentrations were measured, and digital photoplethysmography and ultrasonic duplex scanning of the brachiocephalic arteries were performed. Results Increases in systemic inflammatory (SI) markers were found: median ESR was 25 [4.00; 45.00] mm/h (N<20), CRP was 7.5 [1.30; 17.10] mg/l (N<5), and fibrinogen was 4.30 [1.30; 8.30] g/l (N 1.8-4.0). Vascular remodeling was detected. In the large arteries: the median alternative large artery stiffness index (aSI) was 8.30 [6.10; 15.80] (N10), intima-media thickness (IMT) was 0.92 [0.85; 1.30] mm (N<0.90), and carotid-femoral pulse wave velocity (cfPWV) was 9.26±1.59 (95% CI: 8.49-10.59) m/s (N1.8). According to the rank correlation analysis (Spearman rank correlation coefficient), significant direct corrlations were found between CRP and aSI ( ρ =0.575; p =0.001), IMT ( ρ =0.497; p =0.005); fibrinogen and aSI ( ρ =0.662; p =0.001), IMT ( ρ =0.678; p =0.001). Also, aSI and IMT were significantly worse in the groups with elevated CRP ( ρ =0.001; p =0.042) and in patients with a more advanced tumor process according to the Ann-Abor staging system ( ρ =0.002; p =0.001). However, the severity of SI and vascular remodeling did not differ in patients with different cardio-oncological risks. Conclusion Patients with hemoblastosis before the start of polychemotherapy have morpho-functional changes in blood vessels associated with cancer severity and SI intensity. These results may indicate the potential prognostic value of routine SI markers and evaluation of baseline vascular status for stratification of cardio-oncological risk. Further studies in larger patient samples and assessment of long-term outcomes are needed to clarify these findings.

Verified
Journal Article
Open access
PDF file
DKDaria Kutsakina
Daria Kutsakina
ACAlexandra Dmitrievna Chernichkina
Alexandra Dmitrievna Chernichkina
NNNadezhda Nikolaeva
Nadezhda Nikolaeva
OVOlga O. Voronkova
Olga O. Voronkova
OTOlga Valerevna Tashchyan
Olga Valerevna Tashchyan
APAlexander Sergeevich Panferov
Alexander Sergeevich Panferov
Background: Crohn‘s disease (CD) is frequently complicated by extraintestinal manifestations, including axial spondyloarthritis (axSpA). Both diseases share genetic (HLA-B27, IL23R, ERAP1/2) and immunopathological mechanisms (Th17/IL-23 axis). Their co-occurrence increases the risk of systemic complications such as AA amyloidosis. Case presentation: We report a 42-year-old male with HLA-B27-positive axSpA who developed CD shortly after initiating secukinumab (IL-17A inhibitor). Following discontinuation of secukinumab and surgical management of CD, the patient experienced rapidly progressive AA amyloidosis affecting the kidneys and intestines, leading to acute kidney injury and requiring hemodialysis. Potential triggering factors included a preceding intestinal infection and self-administered infrared physiotherapy. Conclusions: Coexistent CD and axSpA significantly increases the risk of severe AA amyloidosis. IL-17 inhibitors should be used with extreme caution in patients with subclinical or active CD. Early screenings for proteinuria and low-threshold biopsy are essential to detect AA amyloidosis. In patients with both conditions, TNF-α or IL-12/23 inhibitors are preferred over IL-17 blockade.

30 June 2024 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
MKMaria Kozhevnikova
Maria Kozhevnikova
KЕKorobkova Е.о.
Korobkova Е.о.
DKDaria Kutsakina
Daria Kutsakina
PAPanova A.L.
Panova A.L.
SASvetlana Appolonova
Svetlana Appolonova
Currently, the combination of chronic heart failure (CHF) and chronic kidney disease (CKD) is considered within the framework of the cardiorenal syndrome, which is associated with a high risk of adverse outcomes. The purpose of this work is to is determine the concentration of one of the most important biologically active substances – histamine and assess histamine level in patients with cardiovascular and renal pathology. The study included 498 patients: 315 patients of the main group suffering from cardiovascular diseases, some of them also having CKD; comparison group – 83 healthy patients. The levels of histamine in the blood plasma of patients were assessed by high-performance liquid chromatography combined with mass spectrometry (HPLC-MS). Based on the results of the analysis, the following data were obtained: plasma levels of histamine in patients with cardiovascular diseases were lower than in healthy patients. The lowest concentration was observed in the group of patients with CHF. Also it was found, that histamine levels are significantly associated with the presence of CKD, while a correlation analysis of histamine levels and laboratory parameters revealed a direct correlation of moderate strength between histamine levels and glomerular filtration rate (GFR) (r=0,421, p<0,000001). The results indicate the role of histamine in the pathogenesis of the cardiorenal syndrome, which requires further research in this direction.

22 September 2025 in Journal Infectology
Verified
Journal Article
Open access
PDF file
ADA. A. Demina
A. A. Demina
DKDaria Kutsakina
Daria Kutsakina
NNNadezhda Nikolaeva
Nadezhda Nikolaeva
OVOlga O. Voronkova
Olga O. Voronkova
DBD. A. Budanova
D. A. Budanova
YBYuri Belenkov
Yuri Belenkov
The COVID-19 pandemic has led to global consequences, including Long-COVID. This term is used to refer to the symptoms of a new coronavirus infection that last more than 4 weeks, but less than 12 weeks from the onset of the disease. The most common symptoms are shortness of breath, cough, and general weakness. The risk group for the long-term course of COVID-19 includes patients with immunodeficiency. One of the reasons for the long-term persistence of symptoms is the persistence of the virus in the body. However, in 30–40% of cases, the results of the SARS-CoV-2 test turn out to be negative, which makes it difficult to make a diagnosis. In addition, patients with immunodeficiency against Long-COVID may develop opportunistic infections caused by reactivated opportunistic microflora against the background of lymphopenia. The presented clinical example demonstrates a case of Long-COVID infection complicated by the development of pneumocystis pneumonia in a patient with follicular lymphoma. Timely diagnosis and initiation of specific treatment made it possible to stabilize the patient’s condition and prevent the fulminant course of pneumocystis infection.

3 December 2025 in Drug development & registration
Verified
Journal Article
Open access
PDF file
VVValeria Varzieva
Valeria Varzieva
KSKsenia Shestakova
Ksenia Shestakova
ABA. A. Boldin
A. A. Boldin
DKDaria Kutsakina
Daria Kutsakina
YKYu. Yu. Kirichenko
Yu. Yu. Kirichenko
ЮКЮ. Ю. Кириченко
Ю. Ю. Кириченко
Introduction. Multiple myeloma (MM) is a malignant disease of plasma cells characterized by marked heterogeneity of the clinical course and variability in response to treatment. Metabolomic analysis, which reflects the totality of small molecules in biological fluids, opens up new possibilities for the search for diagnostic and prognostic biomarkers. Aim. To evaluate metabolomic profiles of patients with multiple myeloma (MM) and to identify metabolic markers associated with the efficacy of polychemotherapy. Materials and methods. The study was conducted from September 2022 to May 2025 at the Department of Hospital Therapy No. 1 of Sechenov University. We performed targeted analysis of plasma metabolites in 29 pre-treatment MM patients and 30 healthy volunteers (controls). Patients were divided into response and no response groups based on the results of therapy with VCD protocol after three courses. Results and discussion. Significant differences in metabolomic profiles of MM patients compared to controls were found. MM patients showed increased tryptophan catabolism via the kynurenine pathway (~41 % increase in kynurenine/tryptophan ratio, ~80 % decrease in serotonin levels), changes in urea and nitric oxide cycle metabolites (~28 % decrease in arginine, ~5.3-fold increase in asymmetric dimethylarginine), and amino acid imbalances (decrease in serine, aspartate, BCAA) and a significant increase in total acylcarnitines (~1.4-fold higher than control). The baseline metabolic profile also differed between patients with different treatment outcomes: before treatment, patients who subsequently showed a clinical response had lower levels of several acylcarnitines and tryptophan breakdown products (e.g. anthranilic acid), whereas patients without response showed decreased levels of 5-hydroxytryptophan, indole-3-lactic acid and histidine. Conclusions. Metabolomic analysis revealed characteristic metabolic alterations in MM reflecting activation of immunometabolic pathways (tryptophan kynurenine pathway, arginine metabolism) and impaired energy and amino acid regulation. The results indicate the potential prognostic significance of metabolites: a number of biomarkers (e.g. tryptophan derivatives, acylcarnitines) may be associated with chemotherapy sensitivity. The findings open the prospects for further research on metabolic approaches in MM monitoring and therapy.